Skip to main content

Table 1 Characteristics of included studies

From: Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis

Study

Drug

Subjects, N

Male (%)

Mean age, years (SD)

Mean % predicted FEV1 (SD)

Treatment duration, weeks

Asai et al. (2015) [17]

SFC 50/250 µg, bid

26

25 (96)

64.7 (9.31)

1.983 (0.5797)

12

 

Placebo

26

26 (100)

62.2 (8.06)

2.044 (0.4638)

 

Zhong et al. (2015) [22]

QVA149 110/50 μg, qd

372

341 (91.7)

64.8 (7.8)

51.6 (12.8)

26

 

SFC 50/500 μg, bid

369

331 (89.7)

65.3 (7.9)

52.0 (12.9)

 

Bhatt et al. (2017) [15]

FF/VI 100/25 μg, qd

141

104 (77)

68.5 (8.0)

1.29 (0.43)

24

 

VI 25 μg, qd

158

118 (77)

68.7 (7.7)

1.24 (0.42)

 
 

Placebo

145

119 (84)

68.2 (8.1)

1.30 (0.44)

 

Dransfield et al. (2013) [16]

VI, 25 μg, qd

818

474 (58)

63·6 (9·4)

1·3 (0·5)

52

 

FF/VI 50/25 µg, qd

820

476 (58)

63·6 (9·4)

1·3 (0·5)

 
 

FF/VI 100/25 μg, qd

806

453 (56)

63·8 (9·2)

1·3 (0·5)

 
 

FF/VI 200/25 µg, qd

811

467 (57)

63.7 (9.0)

1·3 (0·5)

 

Kerwin et al. (2013) [23]

FF 100 μg, qd

206

132 (64)

62.7 (9.47)

46.9 (12.73)

24

 

VI 25 μg, qd

205

140 (68)

63.4 (9.58)

49.9 (12.05)

 
 

FF/VI 50/25 μg, qd

206

135 (66)

62.8 (9.13)

48.4 (12.66)

 
 

FF/VI 100/25 μg, qd

206

137 (67)

62.3 (8.49)

47.8 (12.28)

 
 

Placebo

207

141 (68)

62.1 (8.80)

48.5 (12.46)

 

Maltais et al. (2002) [24]

BUD 2 mg q6h

71

57 (80.2)

69.1 (8.7)

1.14 (0.45)

1.5

 

Placebo

66

53 (80.3)

70.4 (8.9)

1.13 (0.44)

 

Martinez et al. (2013) [25]

FF 100 μg, qd

204

150 (74)

61.8 (8.28)

48.4 (12.17)

24

 

FF 200 μg, qd

203

151 (74)

61.8 (9.02)

47.1 (11.98)

 
 

VI 25 μg, qd

203

151 (74)

61.2 (8.62)

48.5 (12.89)

 
 

FF/VI 100/25 μg, qd

204

144 (71)

61.9 (8.79)

48.1 (12.85)

 
 

FF/VI 200/25 μg, qd

205

137 (67)

61.1 (8.58)

47.1 (12.76)

 
 

Placebo

205

152 (74)

61.9 (8.14)

48.3 (12.71)

 

Sharafkhaneh et al. (2012) [26]

BUD/FM 320/9 μg bid

407

262 (64.4)

63.8 (9.4)

37.9 (11.8)

48

 

BUD/FM 160/9 μg bid

408

264 (64.7)

62.8 (9.2)

37.6 (11.6)

 
 

FM 9 μg bid

403

229 (56.8)

62.5 (9.4)

37.5 (12.4)

 

Siler et al. (2016) [27]

FF/VI 100/25 μg, qd

806

605 (75)

65.3 (8.58)

50.3 (10.33)

12

 

VI 25 μg, qd

814

625 (77)

65.4 (9.02)

50.5 (10.33)

 

Vogelmeier et al. (2013) [28]

QVA149 110/50 μg, qd

258

181 (70.2)

63·2 (8·2)

60·5 (10·5)

26

 

SFC 50/500 μg, bid

264

189 (71.6)

63·4 (7·7)

60·0 (10·7)

 

Vestbo et al. (2016) [29]

FF 100 μg, qd

4157

3053 (73.8)

65 (8)

59·6 (6·1)

96

 

VI 25 μg, qd

4140

3053 (74.1)

65 (8)

59·7 (6·1)

 
 

FF/VI 100/25 μg, qd

4140

3112 (75.5)

65 (8)

59·7 (6·1)

 
 

Placebo

4131

3071 (74.7)

65 (8)

59·7 (6·1)

 

Wedzicha et al. (2014) [30]

BDP/FOR 100/6 μg × 2, bid

601

408 (69)

64.6 (8.6)

41.9 (6.0)

48

 

FOR 12 μg, bid

596

410 (69)

63.9 (8.6)

41.6 (6.0)

 

Zheng et al. (2014) [31]

FF/VI 50/25 μg, qd

160

144 (90)

65.2 (8.41)

47.5 (14.21)

24

 

FF/VI 100/25 μg, qd

161

149 (93)

65.1 (9.19)

49.6 (13.19)

 
 

FF/VI 200/25 μg,

160

145 (91)

62.7 (8.65)

48.2 (13.63)

 
 

Placebo

162

146 (90)

64.7 (8.78)

48.6 (13.39)

 

Lipson et al. (2018) [18]

FF/UMEC/VI 100/62.5/25 μg, qd

4151

2766 (66.6)

65.3 (8.2)

45.7 (15.0)

52

 

FF/VI 100/25 μg, qd

4134

2748 (66.5)

65.3 (8.3)

45.5 (14.8)

 
 

UMEC/VI 62.5/25 μg, qd

2070

1356 (65.5)

65.2 (8.3)

45.4 (14.7)

 

NCT00857766 [32]

FSC 250/50 μg, bid

123

68 (55.3)

63.6 (8.92)

 

16

 

Matching Placebo

126

74 (58.7)

63.5 (7.88)

  

Wedzicha et al. (2016) [19]

QVA149 110/50 μg, qd

1678

1299 (77.3)

64.6 (7.9)

44.0 (9.5)

52

 

SFC 50/500 μg, bid

1680

1258 (74.8)

64.5 (7.7)

44.1 (9.4)

 

NCT03474081 [33]

FF/UMEC/VI 100/62.5/25 μg, qd

400

274 (68.5)

66.2 (8.08)

 

12

 

Tiotropium 18 μg, qd

399

269 (67.3)

66.1 (7.78)

  
  1. FF fluticasone furoate; VI vilanterol; SFC salmeterol/fluticasone propionate; QVA149 indacaterol/glycopyrronium; BUD budesonide; FM formoterol; BDP/FOR beclomethasone dipropionate/formoterol fumarate; UMEC umeclidinium; FSC Fluticasone Propionate/Salmeterol; FEV1 forced expiratory volume in 1 second